Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.
Oudard S, Geoffrois L, Guillot A, Chevreau C, Deville JL, Falkowski S, Boyle H, Baciuchka M, Gimel P, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Denechere G, Amela EY, Abadie-Lacourtoisie S, Gross-Goupil M. Oudard S, et al. Eur J Cancer. 2016 Jul;62:28-35. doi: 10.1016/j.ejca.2016.04.003. Epub 2016 May 15. Eur J Cancer. 2016. PMID: 27192659
Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
Oudard S, Caty A, Humblet Y, Beauduin M, Suc E, Piccart M, Rolland F, Fumoleau P, Bugat R, Houyau P, Monnier A, Sun X, Montcuquet P, Breza J, Novak J, Gil T, Chopin D. Oudard S, et al. Ann Oncol. 2001 Jun;12(6):847-52. doi: 10.1023/a:1011141611560. Ann Oncol. 2001. PMID: 11484963 Free article. Clinical Trial.
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.
Escudier B, Droz JP, Rolland F, Terrier-Lacombe MJ, Gravis G, Beuzeboc P, Chauvet B, Chevreau C, Eymard JC, Lesimple T, Merrouche Y, Oudard S, Priou F, Guillemare C, Gourgou S, Culine S; Genitourinary Group of the French Federation of Cancer Centers. Escudier B, et al. Among authors: oudard s. J Urol. 2002 Sep;168(3):959-61. doi: 10.1016/S0022-5347(05)64551-X. J Urol. 2002. PMID: 12187199 Clinical Trial.
Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Djeridane M, Oudard S, Escoffre-Barbe M, Lacotte-Thierry L, Desablens B, Briére J, Dib M, Cassasus P, Ghandour C, Lamy T, Lejeune F, Simon M, Traullé C, Vigier M, Maisonneuve H, Briére J, Colonna P, Andrieu JM. Djeridane M, et al. Among authors: oudard s. Cancer. 2002 Nov 15;95(10):2169-79. doi: 10.1002/cncr.10932. Cancer. 2002. PMID: 12412171 Free article. Clinical Trial.
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J; Subcutaneous Administration Propeukin Program Cooperative Group. Tourani JM, et al. Among authors: oudard s. J Clin Oncol. 2003 Nov 1;21(21):3987-94. doi: 10.1200/JCO.2003.02.073. J Clin Oncol. 2003. PMID: 14581421 Clinical Trial.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Motzer RJ, et al. Among authors: oudard s. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044. N Engl J Med. 2007. PMID: 17215529 Free article. Clinical Trial.
Sorafenib in advanced clear-cell renal-cell carcinoma.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Escudier B, et al. Among authors: oudard s. N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655. N Engl J Med. 2007. PMID: 17215530 Free article. Clinical Trial.
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, Arakelyan N, Culine S; GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales). Oudard S, et al. J Urol. 2007 May;177(5):1698-702. doi: 10.1016/j.juro.2007.01.063. J Urol. 2007. PMID: 17437788 Clinical Trial.
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.
Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G; Renal Insufficiency and Cancer Medications (IRMA) Study Group. Launay-Vacher V, et al. Among authors: oudard s. Cancer. 2007 Sep 15;110(6):1376-84. doi: 10.1002/cncr.22904. Cancer. 2007. PMID: 17634949 Free article.
438 results